Looks like ZYESAMI has a higher mortality rate than standard of care treatment. That sure sounds bad to me.
I'd much prefer to use Leronlimab which is already proven to be safer than SOC in the CD10 trial.
(2)
(0)
CytoDyn Inc (CYDY) Stock Research Links
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.